CompletedPhase 3ACTRN12605000324617
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN I & ATTAIN II)
Sponsor
Theravance, Inc.
Enrollment
750 participants
Start Date
Feb 1, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- Diagnosis of hospital acquired pneumonia.
Exclusion Criteria1
- More than 24 hours of prior therapy unless a treatment failure. Pregnancy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Telavancin 10 mg/kg q 24 hours IV
Telavancin 10 mg/kg q 24 hours IV
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000324617
Related Trials
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
NCT0613449228 locations
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
NCT057331041 location
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype
NCT0626990026 locations
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
NCT059795454 locations